Arthur M. The Mercurio [43] reported that the anti-tumor immune response can be enhanced by reducing the targeting of VEGF, and that VEGF promotes the vascular immune barrier through VEGF receptor activity on endothelial cells, which indirectly interferes with immune cell trafficking and leads to immune tolerance at tumor sites, and by targeting VEGF receptors and their drugs, VEGF expression can be effectively reduced and anti-tumor immune responses can be restored. The gene discussed is VEGFA; the disease is neoplasm.